Prothena Corp Public (PRTA) Free Cash Flow Growth (1y) (2013 - 2026)
Prothena Corp Public (PRTA) Free Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 137.65% |
| 10 | Prothena Corp Public | 471.02 Mn | 141.56 Mn | - | 154.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 154.07% |
| Dec 31, 2025 | 51.25% |
| Sep 30, 2025 | 10.22% |
| Jun 30, 2025 | -393.54% |
| Mar 31, 2025 | 27.00% |
| Dec 31, 2024 | 9.07% |
| Sep 30, 2024 | -598.02% |
| Jun 30, 2024 | 134.61% |
| Mar 31, 2024 | -53.99% |
| Dec 31, 2023 | -925.69% |
| Sep 30, 2023 | 129.00% |
| Jun 30, 2023 | -29.00% |
| Mar 31, 2023 | -26.90% |
| Dec 31, 2022 | 77.49% |
| Sep 30, 2022 | -127.97% |
| Jun 30, 2022 | -196.74% |
| Mar 31, 2022 | -11.04% |
| Dec 31, 2021 | -18.97% |
| Sep 30, 2021 | 674.42% |
| Jun 30, 2021 | 295.37% |